# Sanofi CDR (CAD Hedged) (SNY.TO) fundamentals

Data as of 2026-11-04. TSX, Canada. Sector: Healthcare / Pharmaceuticals. Price C$21.14, market value C$25.3 billion.

## Valuation
- **P/E (trailing): 22.7×** (5-yr avg 3.2×, 3-yr avg 3.2×). Sanofi CDR (CAD Hedged) trades at 22.7× trailing earnings, well above its own five-year average of 3.2×: investors are paying up relative to the company's past. The Healthcare median in the September 2026 study was 28.5×.
- **Price / sales: 0.5×**. Each dollar of revenue is priced at 0.5×, a low multiple typical of thin-margin businesses or out-of-favour stocks.
- **Price / book: 0.4×**. The shares trade below book value, which can signal a bargain or a balance sheet the market doubts.
- **EV / EBITDA: 4.5×**. Enterprise value is 4.5× operating earnings before depreciation, the multiple that ignores how the company is financed; below 8× is inexpensive for most sectors.
- **Free-cash-flow yield: 27.7%** (5-yr avg 28.9%). Free cash flow equals 27.7% of the market value, in line with its five-year average of 28.9%. Above 5% is generally attractive.
- **Earnings yield: 4.4%**. The inverse of the P/E: 4.4% of the price is earned each year.

## Profitability
- **Gross margin: 72.8%**. Sanofi CDR (CAD Hedged) keeps 72.8% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 20.6%**. 20.6% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: 16.7%**. 16.7% of each dollar of sales reaches the bottom line.
- **Return on equity: 10.9%**. 10.9% on shareholders' equity is solid.
- **Return on invested capital: 9.4%**. Return on all capital, debt included, is 9.4%.
- **Return on assets: 3.1%**. Each dollar of assets produces 3.1% of profit.

## Growth
- **Revenue growth (1 yr): 5.5%** (3-yr 4.8%/yr). Revenue grew 5.5% over the last year.
- **EPS growth (1 yr): 39.4%** (3-yr 6.0%/yr). Earnings per share rose 39.4%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): -5.0%/yr**. Free cash flow has compounded at -5.0% a year over three years, lagging earnings: check whether profits are turning into cash.

## Financial health
- **Debt to equity: 0.28**. Debt is 0.28 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 1.4×**. It would take 1.4 years of operating earnings to repay net borrowings, within the comfortable range.
- **Interest coverage: 13.8×**. Operating profit covers interest 13.8× over, a safe margin.
- **Current ratio: 1.09** (quick 0.73). Current assets cover the next year's liabilities 1.09 times.
- **Altman Z-score: 1.70**. A Z-score of 1.70 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 7/9**. 7 of 9 fundamental checks pass: strong and improving financials.

## Dividends
- **Dividend: none**. Sanofi CDR (CAD Hedged) does not currently pay a dividend.

## Price and momentum
- **From 52-week high: -6.3%** (16.6% above the low). Trading 6% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 75**. An RSI of 75 is in overbought territory; short-term pullbacks are common from here.
- **Beta (1 yr): 0.10** (volatility 26%). Beta of 0.10 against the S&P/TSX Composite: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=SNY.TO · Page: https://foliofundamentals.com/stocks/sny.to

Not investment advice.